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Purpose: Inappropriate use of an inhaled corticosteroid (ICS) for COPD has clinical and 
economic disadvantages. This retrospective analysis of The UK Health Improvement Network 
(THIN) database identified factors influencing treatment escalation (step-up) from a long-
acting muscarinic antagonist (LAMA) to triple therapy (LAMA + long-acting β-agonist-ICS). 
Secondary objectives included time to step up from first LAMA prescription, Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) grouping (2011/2013, 2017), and Medical 
Research Council (MRC) grade prior to treatment escalation.
Materials and methods: Data were included from 14,866 people $35 years old with a 
COPD diagnosis (June 1, 2010–May 10, 2015) and initiated on LAMA monotherapy. The most 
commonly used LAMA at baseline was tiotropium (92%).
Results: Multivariate analysis (10,492 patients) revealed that COPD exacerbations, lower forced 
expiratory volume in 1 second (FEV
1
), “asthma”, MRC grade, proactive and reactive COPD 
primary care, elective secondary-care contact, cough, and number of short-acting bronchodilator 
prescriptions were positively associated with treatment escalation (P,0.05). Being older, a 
current/ex-smoker, or having increased sputum symptom codes were negatively associated with 
treatment escalation (P,0.05). Median MRC score was 2 at baseline and 3 prior to treatment 
escalation. Using the last MRC reading and exacerbation history in the year prior to escalation, 
GOLD 2017 groupings were A 27.4%, B 37.3%, C 15.3%, and D 20%. In patients with avail-
able FEV
1
 measures, exacerbations, and MRC code (n=1,064), GOLD 2011/2013 groupings 
were A 20.4%, B 19.2%, C 24.8%, and D 35.6%.
Conclusion: While the presence of COPD exacerbations seems to be the main driver 
for treatment escalation, according to the 2017 GOLD strategy many patients appear to be 
overtreated, as they would not be recommended for treatment escalation. Reviewing patients’ 
treatment in the light of the new GOLD strategy has the potential to reduce inappropriate use 
of triple therapy.
Keywords: inhaled corticosteroid, treatment step-up, GOLD 2017 grouping, patient 
overtreatment
Plain-language summary
In patients with COPD initiated on long-acting muscarinic antagonist monotherapy, this study 
identified that COPD exacerbations, lower forced expiratory volume in 1 second, “asthma”, and 
health-care contact were associated with escalation to triple therapy (long-acting muscarinic 
antagonist + long-acting β-agonist + inhaled corticosteroid [ICS]). When treatment practices 
were analyzed according to the 2017 Global Initiative for Chronic Obstructive Lung Disease 
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strategy, many patients appeared to be overtreated, particularly 
with respect to prescription of triple therapy comprising ICSs. 
Understanding factors associated with the escalation of treatment 
to include ICSs may improve treatment practices in patients with 
COPD and bring them in line with the 2017 Global Initiative for 
Chronic Obstructive Lung Disease strategy, and moreover reduce 
the inappropriate, expensive, and potentially harmful overprescrib-
ing of ICSs for COPD.
Introduction
COPD is a complex respiratory disorder characterized by 
persistent airflow limitation that is usually progressive in 
nature and a major cause of morbidity and mortality.1–3 The 
World Health Organization estimates that approximately 
3 million people died of COPD worldwide in 2015 (5% of all 
deaths), and predicts that due to higher smoking prevalence 
and aging populations in many countries, the prevalence of 
COPD is likely to increase in the future.4
The updated 2017 Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) strategy categorizes patients 
into four grades of airflow obstruction (1–4), based on per-
centage of predicted forced expiratory volume in 1 second 
(FEV
1
), and into four risk groups (A–D), based on symp-
toms and exacerbation history.2,3 The previous 2011 GOLD 
strategy (which was slightly adapted in 2013) used the degree 
of airflow obstruction to contribute to A–D grouping, such 
that those individuals with FEV
1
 ,50% were considered 
in groups C and D.1 In 2013, GOLD made a minor update 
and treated patients with one hospitalized exacerbation 
the same as patients with two or more nonhospitalized 
exacerbations.1
Long-term treatment with an inhaled corticosteroid 
(ICS) in combination with a long-acting β-agonist (LABA) 
is recommended therapy for certain patients in GOLD 
2011/2013 groups C and D, but now there are preferred 
pathways that recommend optimal bronchodilation using 
a long-acting muscarinic antagonist (LAMA) or LAMA + 
LABA before the addition of ICS therapy (as triple therapy) 
in patients whose symptoms are not adequately controlled.3 
In some patients, such as those with a history and/or findings 
suggestive of an asthma–COPD overlap, LABA–ICS therapy 
may be the first choice, but other options should also be 
considered.3 Despite these treatment pathways indicating 
appropriate prescription of ICSs, real-world data suggest that 
ICSs may be prescribed inappropriately in some patients. 
For example, in a study of more than 24,000 electronic 
patient records and patient-completed questionnaires from 
a large UK primary-care database, ~50% of patients in both 
the overall cohort (n=24,957) and the cohort with moderate 
airflow limitation (n=13,557) were receiving ICSs, either 
in combination with a LABA (26.7% for both cohorts) or 
in combination with a LABA and a LAMA (23.2% and 
19.9%, respectively).5 These findings revealed that an ICS in 
combination with LABA or LABA + LAMA was the most 
frequently used treatment in patients in GOLD group A or B, 
and that ICSs had been prescribed in 49% of patients with 
moderate airflow obstruction and no exacerbations in the 
previous year.5 In light of this, the authors concluded that 
ICSs were prescribed irrespective of the severity of airflow 
limitation, asthma diagnosis, and exacerbation history,5 
which is not in accordance with the 2017 GOLD strategy.3 
Studies of ICS withdrawal, even in COPD patients with a 
history of exacerbations, have shown strategies can be safely 
undertaken that enable patients to change to a more appropri-
ate therapy according to up-to-date guidances.6,7
The potentially inappropriate use of ICSs in patients with 
COPD has economic and clinical implications,8–12 being 
associated with an increased risk of adverse events, includ-
ing pneumonia, osteoporosis, diabetes, and cataracts.8 The 
increased risk of pneumonia, for example, is particularly 
well documented.9–12 The economic impact of COPD and 
its treatment costs are considerable. For example, the UK 
National Institute for Health and Care Excellence (NICE) 
estimated that COPD costs the National Health Service 
(NHS) over £268 million in prescriptions alone (based on 
2011 data).13 Furthermore, the net ingredient cost of prepa-
rations containing ICSs for respiratory disease (asthma and 
COPD) in England alone has been estimated to be in excess 
of £700 million, based on 2014 data.13 If ICSs are inappro-
priately prescribed to certain patients, it is one more factor 
adding to the already high economic and social burden 
associated with COPD.
Guidelines from expert panels, such as GOLD, are 
developed and routinely updated to aid most appropriate 
treatment practices, supported by clinical observations. 
Therefore, understanding the pathway and predictors for 
treatment escalation in COPD may help identify patients for 
whom alternative treatment strategies or treatment escala-
tion without ICSs may be more appropriate. This study was 
conducted to determine the factors influencing treatment 
escalation (step-up) to a LAMA + LABA–ICS fixed-dose 
combination (FDC) inhaler (triple therapy) in patients with 
COPD who had been initiated on LAMA monotherapy, and 
included assessment of patients and their treatment using 
both the GOLD 2011/2013 and the more up-to-date GOLD 
2017 classification criteria.1,3 The primary objective was to 
identify factors significantly associated with time to step-up 
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from LAMA monotherapy to LAMA + LABA–ICS (triple 
therapy). Secondary objectives included assessing time to 
step-up from first LAMA prescription, GOLD category 
according to 2017 criteria, and change in breathlessness 
(Medical Research Council [MRC]) score prior to treat-
ment escalation.
Materials and methods
Study design
This was a retrospective analysis of anonymized electronic 
medical records (EMRs) in The UK Health Improvement 
Network (THIN) database, a primary-care EMR-data 
resource with 3 million active patients and 385 active GP 
practices. Patients were representative of the UK population 
by age, sex, medical conditions, and death rates adjusted for 
demographics and social deprivation. The EMRs were con-
sistently updated and could be followed over time. The GPs 
contributing data to THIN provided health services under 
the terms of the UK’s NHS.14
The THIN data-collection scheme is approved by the UK 
South-East Multicentre Research Ethics Committee (SRC). 
Approval for this study was gained from the IMS Health 
Independent Scientific Board (SRC reference 16THIN, 
approval March 29, 2016). The study was conducted in 
accordance with legal and regulatory requirements and fol-
lowed research practices described in the Guidelines for Good 
Pharmacoepidemiology Practices issued by the International 
Society for Pharmacoepidemiology, International Society 
for Pharmacoeconomics and Outcomes Research guidance, 
and Pharmaceutical Research and Manufacturers Associa-
tion guidelines.
Study periods
The study period included data until May 10, 2016, and 
was the time from the index event (date of first LAMA pre-
scription) until the time that the patient received LAMA + 
LABA–ICS (triple therapy, defined as any LABA–ICS 
FDC prescription after initiation of LAMA monotherapy; 
patients must have also received a LAMA within 2 months 
of treatment escalation). Patients were included if they had 
a COPD diagnosis between June 1, 2010 and May 10, 2015, 
allowing for at least 1 year of follow-up.
Participants
Data were extracted for patients who had a diagnosis of 
COPD (excluding an asthma diagnosis) who were $35 years 
old and who had received LAMA monotherapy only 
(aclidinium, glycopyrronium, tiotropium, or umeclidinium) 
as initial COPD treatment prior to treatment escalation. 
Data from patients who started therapy comprising a 
LAMA in combination with any other COPD maintenance 
therapy (LABA, ICS, or LABA–ICS FDC) or who had a 
history of LAMA, LABA, LABA–LAMA FDC, ICS, or 
LABA–ICS use in the 2-month (60-day) preindex period 
were excluded. Use of reliever medications, mucolytics, and 
xanthines was accepted.
Statistical analysis
As the study was a retrospective noninterventional database 
analysis of anonymized patient records, a formal sample size 
was not calculated. A feasibility calculation was carried out to 
assess the potential size of the population to be studied. SAS 
version 9.4 (SAS Institute, Cary, NC, USA) was used for all 
analyses. No missing data imputations and no multiplicity 
adjustments were performed.
Patient characteristics and comorbidities recorded at 
any time are summarized descriptively (Table S1). Time to 
treatment escalation (step-up) was assessed using univariate 
and multivariable Cox regression incorporating time-varying 
covariates.15 The univariate analysis included 14,866 patients, 
and any missing data due to missing covariates were censored 
for that observation. For the multivariate Cox regression, 
to ensure inclusion of patients who had FEV
1
 and MRC 
recorded, the final data set was reduced to 10,492. Statisti-
cally significant time-varying covariates were included in 
the final model using a stepwise model-selection procedure. 
Factors significantly associated with treatment escalation 
(P,0.05) were retained in the model.
In the prespecified analysis plan, the following initial 
terms were included in the multivariate analysis selection: age, 
sex, FEV
1
, physician-coded asthma, chronic kidney disease, 
mental health disorders, depression, anxiety, osteoporosis, 
rheumatoid arthritis, lung cancer, obesity, epilepsy, diabetes, 
pneumonia, MRC grade, smoking status, cough symptoms 
(number of consultations with code for cough), sputum symp-
toms (number of consultations with code for sputum), short-
acting bronchodilator use, proactive COPD primary care 
(defined as COPD monitoring [including by doctor or nurse], 
shared-care disease monitoring, COPD 3-, 6-, or 12-month 
review follow-up, COPD health education, COPD-medication 
optimization, issue of COPD rescue pack or advance supply 
of steroid medication or antibiotic medication [or deferred 
antibiotic therapy], COPD leaflet given, has COPD care plan 
or care pathway, COPD clinical management plan, on COPD 
supportive care pathway, seen in COPD clinic), reactive 
COPD primary care (defined as nighttime or out-of-hours 
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visit, follow-up or acute visit, home-, hotel-, or nursing/
residential home visit, twilight visit by the practice, their 
cooperative, deputizing service, or local roster service, reac-
tive or cooperative surgery consultation, minor-injury service, 
medicine management or telephone consultation related to 
COPD), elective secondary-care contact (defined as COPD 
secondary-care consultation or respiratory hospital referral), 
COPD exacerbations (composite end point defined as COPD 
emergency admission or acute exacerbation of COPD, lower 
respiratory tract infection, oral corticosteroids (OCS) and 
antibiotic prescription on same day, according to the defini-
tion used previously),16 and cardiovascular risk (composite 
end point defined as combined comorbidity for cardiovascular 
risk). Cough symptoms, sputum symptoms, proactive and 
reactive COPD primary care, and elective secondary-care 
contact were based on Read code data only.
A stepwise procedure was followed, which is useful where 
there is a large number of potential explanatory variables and 
no underlying theory for the order on which to base the model 
selection. The order of importance of variables automatically 
selected in the stepwise process was: COPD exacerbations 
(composite), FEV
1
, “asthma”, proactive COPD primary care, 
use of short-acting bronchodilators, reactive COPD primary 
care, MRC grade, smoking status, cough symptoms, elective 
secondary-care contact, sputum symptoms, and age. Terms 
were retained in the model if P,0.05.
GOLD grouping was analyzed according to GOLD 
2011/2013 criteria for patients with any FEV
1
, MRC 
available during the last 360 days of the study period (and 
exacerbations/hospitalizations as previously described),1 and 
GOLD 2017 classification criteria for patients with any MRC 
available during the last 360 days of the study period (and 
exacerbations/hospitalizations as previously described).3
Results
Patient baseline characteristics
In total, data from 14,866 patients were included in this analy-
sis (Figure 1): 6,482 of 14,866 (43.6%) received treatment 
escalation, and 8,384 of 14,866 (56.4%) remained on LAMA 
monotherapy. Overall, 1,875 of 14,866 patients (12.6%) were 
lost to follow-up due to death. Patient baseline characteristics 
are given in Table 1. The mean age of the overall popula-
tion was 68 years, and 54% were male. In the treatment-
escalation group, the mean age was 68 years and 55% were 
male. The most commonly used LAMA at baseline was 
tiotropium (92%). Of patients who received treatment esca-
lation, the majority were prescribed fluticasone propionate 
500 µg–salmeterol 50 µg (as Seretide 500 Accuhaler; 29%), 
followed by salmeterol 25 µg–fluticasone 250 µg (as Seretide 
250 Evohaler, 16%). The Seretide 250 Evohaler inhaler 
device does not have a license for the treatment of COPD.
Comorbidities
The most prevalent comorbidities were hypertension (44%), 
chronic heart disease (20%), anxiety (20%), and diabetes 
(15%) (Table 2). Comparison of comorbidities in the popu-
lation studied here with those in the general population of 
England17 suggests that the prevalence of heart failure (6.7% 
vs 0.7%, respectively) and osteoporosis (7.9% vs 0.1%, 
respectively) is greater in this COPD population, as might 
be expected.
Time to treatment escalation
In total, 44% of the cohort received treatment escalation 
(Figure 2). Of these patients, 85% did so within 2 years 
of initiating LAMA monotherapy. The median time to 
treatment escalation from the first LAMA prescription 
was 155 days (interquartile range 422–464 days). In the 
treatment-escalation group, 33% of patients who had an FEV
1
 
recording had FEV
1
 ,50% and 67% had FEV
1
 $50% prior 
to treatment escalation.
Factors associated with treatment 
escalation
Univariate analysis
Factors associated with treatment escalation are reported in 
Table 3, of which COPD exacerbation was associated with 
the highest HR (2.68). Other factors positively associated 
(P,0.05) with treatment escalation included (in decreasing 
order of HR) MRC grade, “asthma”, elective secondary-care 
contact, proactive COPD primary care, pneumonia, cough 
symptoms, reactive COPD primary care, mental health 
disorders, depression, sputum symptoms, anxiety, number 
of short-acting bronchodilator prescriptions, and number 
of steroid prescriptions. Statistically significant factors that 
were negatively associated with treatment escalation were 
older age, higher FEV
1
, and current or ex-smoker status 
(Table 3). A small number of COPD patients in this study 
were recorded as never having smoked. However, the risk 
of treatment escalation for the two larger, more clinically 
relevant patient groups of current smokers and ex-smokers 
was similar (Table 3).
Multivariate analysis
The multivariate analysis included 10,492 patients, 4,591 
of whom received treatment escalation. Observations con-
firmed that COPD exacerbations remained the factor most 
closely associated with treatment escalation (Table 4). 
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Other factors, in decreasing order of HR, were “asthma”, 
MRC grade, proactive COPD primary care, reactive COPD 
primary care, elective secondary-care contact, cough symp-
toms, and number of short-acting bronchodilator prescrip-
tions (all P,0.05). Age at index date, higher FEV
1
, sputum 
symptoms, and being a current or ex-smoker were negatively 
associated with treatment escalation (Table 4).
GOLD grade and group classification of 
patients prior to treatment escalation
The GOLD 2011/2013 group was determined in a subgroup 
of 1,064 patients with FEV
1
 exacerbations and MRC score 
available during the last 12 months of the study period who 
received treatment escalation (Table 5): 60% were classified 
as being in group C or D compared with 40% in A or B. 
The GOLD 2017 group was determined in a subgroup of 
5,090 patients who had received treatment escalation and 
had an MRC score during the last 12 months of the study 
period (Table 5). In total, 35% of patients were classified as 
being in GOLD group C or D compared with 65% in group 
A or B. Similarly, GOLD 2017 grade was determined in 
a subgroup of 1,703 patients who had received treatment 
escalation and had an FEV
1
 score during the last 12 months 
of the study period (Table 5). In total, 67% of patients 
??????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????? ????????????????????????????????????????????????????????? ???????????????????????????
??????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
????????????????????????????????????????? ???????????????????????????
?????????????????????????????
??????????????????????????????????????????????????? ????? ???????????????????????????????
??????????????????????????????????????????????????????????????????????
Figure 1 Cohort selection from THIN database of 8,676,730 patient records.
Note: a% of COPD diagnosis cohort.
Abbreviations: FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; THIN, The UK Health 
Improvement network.
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were classified as being grade 1 or 2 compared with 33% 
grade 3 or 4.
assessment of treatment escalation per 
MRC group
Median MRC scores in the treatment-escalation group 
were 2 (interquartile range 2–3) at baseline (n=3,823) and 
3 (interquartile range 2–3) during the study period (n=5,611, 
Figure 3), suggesting that patients became more breathless 
prior to treatment escalation.
Discussion
This retrospective analysis of the UK THIN database was 
conducted to determine the factors influencing treatment 
escalation to a LAMA + LABA–ICS (triple therapy) in 
patients with COPD who were initiated on LAMA mono-
therapy. To assess prescribing practices at the time of the 
study, we analyzed patients categorized by the then-current 
GOLD 2011/2013 groupings. In addition, as GOLD updated 
their guidance in 2017, we also analyzed patients accord-
ing to the GOLD 2017 strategy. The multivariate analysis 
Table 1 Patient characteristics at baseline
Characteristic All,  
n=14,866
Monotherapy,a 
n=8,384
Treatment escalation,b 
n=6,482
Age, years
Mean ± sD 68.4±10.7 68.8±10.9 67.8±10.5
Range 35–101 35–99 36–101
Sex, n (%)
Female 6,781 (45.6) 3,843 (45.8) 2,938 (45.3)
Male 8,085 (54.4) 4,541 (54.2) 3,544 (54.7)
LAMA therapy initiated, n (%)
Tiotropium handihaler 12,501 (84.1) 6,858 (81.8) 5,643 (87.1)
Tiotropium respimat 1,183 (8) 611 (7.3) 572 (8.8)
aclidinium 623 (4.2) 471 (5.6) 152 (2.3)
Glycopyrronium 487 (3.3) 376 (4.5) 111 (1.7)
Umeclidinium 87 (0.6) 79 (0.9) 8 (0.1)
ICs–laBab stepped up to, n (%)
Fostair NEXThaler 200/6a – – 1 (0.02)
Flutiform 50/5a – – 1 (0.02)
Fostair NEXThaler 100/6 – – 16 (0.25)
DuoResp Spiromax 320/9 – – 19 (0.29)
Flutiform 250/5a – – 24 (0.37)
relvar ellipta 184 µga – – 34 (0.52)
Flutiform 125/5a – – 41 (0.63)
Seretide 50 Evohalera – – 64 (0.99)
relvar ellipta 92 µg – – 139 (2.1)
Symbicort 100/6 Turbohalera – – 154 (2.4)
Seretide 100 Accuhalera – – 178 (2.8)
Seretide 250 Accuhalera – – 399 (6.2)
Fostair 100/6 – – 462 (7.1)
Seretide 125 Evohalera – – 508 (7.8)
Symbicort 200/6 Turbohaler – – 667 (10.3)
Symbicort 400/12 Turbohaler – – 915 (14.1)
Seretide 250 Evohalera – – 1,022 (15.8)
Seretide 500 Accuhaler 1,849 (28.5)
Time to treatment escalation, days
Mean ± sD – – 324.6±392.1
Range – – 1–2,080
Time to end of follow-up,c days
Mean ± sD 535.1±437.7 697.8±400.0 324.6±392.1
Range 0–2,080 0–1,193 1–2,080
Notes: aNot licensed for COPD; bfor the monotherapy group, follow-up was measured up to 1,193 days to reflect a similar period to that of follow-up in the treatment-
escalation group (calculated as the 95th percentile of distribution of the time to escalation); cit may be inappropriate to compare across groups, owing to different lengths of 
follow-up. “–” indicates no data are available.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist.
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demonstrated that COPD exacerbations were the most 
significant factor (ie, had the highest HR) associated with 
treatment escalation, but physician-coded asthma, MRC 
grade, proactive COPD primary care, reactive COPD primary 
care, elective secondary-care contact, cough symptoms, and 
number of short-acting bronchodilator prescriptions were 
also clinically and statistically significantly associated with 
treatment escalation in these patients. The majority of patients 
had their treatment escalated within 2 years. As treatment 
escalation (or step-down) is likely to be initiated during a 
point of contact with a primary-care provider, it would be 
expected that patients with treatment-defined exacerbations 
Table 2 Comorbidities recorded at any time during the study 
period
Comorbidity, n (%) n=14,866
Hypertension 6,603 (44.4)
Chronic heart disease 3,036 (20.4)
Anxiety 2,969 (20)
Diabetes 2,174 (14.6)
Depression 1,967 (13.2)
Asthma 1,965 (13.2)
Cerebrovascular disease 1,695 (11.4)
Atrial fibrillation 1,464 (9.9)
Osteoporosis 1,174 (7.9)
heart failure 990 (6.7)
Mental health disorders (QOF) 882 (5.9)
Obesity 826 (5.6)
Lung cancer 416 (2.8)
Rheumatoid arthritis 380 (2.6)
Epilepsy 337 (2.3)
Chronic kidney disease 247 (1.7)
Abbreviation: QOF, Quality and Outcomes Framework.
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Figure 2 Cumulative time to treatment escalation.
Note: a% of all patients (n=14,866).
Table 3 Univariate Cox regression analysis with significant 
(P,0.05) unadjusted predictors of treatment escalation
Characteristics Univariate analysis, n=14,866
HR 95% CI P-value
Composite: COPD 
exacerbationsa
2.675 2.534–2.823 ,0.0001
MRC grade (vs 1) ,0.0001
grade 5 2.489 2.009–3.083 ,0.0001
grade 4 1.988 1.781–2.219 ,0.0001
grade 3 1.571 1.434–1.721 ,0.0001
grade 2 1.183 1.086–1.288 0.0001
Asthma 2.21 2.079–2.35 ,0.0001
Elective secondary-care contact 1.466 1.371–1.569 ,0.0001
Proactive COPD primary careb 1.303 1.275–1.332 ,0.0001
Pneumonia 1.246 1.147–1.354 ,0.0001
Number of cough symptomsc 1.209 1.183–1.236 ,0.0001
Reactive COPD primary cared 1.191 1.1–1.29 ,0.0001
Mental health disorders 1.187 1.075–1.311 0.0007
Depression 1.160 1.082–1.243 ,0.0001
Number of sputum symptomse 1.149 1.108–1.193 ,0.0001
Anxiety 1.125 1.06–1.194 0.0001
Number of short-acting 
bronchodilator prescriptions
1.041 1.038–1.045 ,0.0001
Number of steroid prescriptions 1.026 1.023–1.028 ,0.0001
Agef 0.997 0.995–1.00 0.0251
FeV1 0.979 0.976–0.982 ,0.0001
Smoking status (vs never smoked)
Current 0.716 0.649–0.791 ,0.0001
ex 0.769 0.697–0.848 ,0.0001
Notes: Data ordered by HR. aComposite end point: if COPD emergency admission 
or aeCOPD or lrTI or OCs + antibiotic occurred on the same day, 1 was assigned 
(otherwise 0). We used time-varying covariates (so patient had 0 assigned until the 
first occurrence of any of those). This has been validated in a previous paper.16 bCOPD 
monitoring; disease monitoring by doctor; disease monitoring by nurse; shared-care 
disease monitoring; COPD 3-monthly, 6-monthly, and annual reviews; COPD follow-
up; COPD health education; COPD-medication optimization; issue of COPD rescue 
pack or advance supply of steroid medication or antibiotic medication or deferred 
antibiotic therapy; COPD leaflet given, has COPD-care plan; has COPD-care 
pathway; has COPD clinical management plan; on COPD supportive care pathway; 
seen in COPD clinic. cNumber of consultations with code for cough: C/O – cough, 
dry cough, productive cough – clear sputum, productive cough – green sputum, 
productive cough – yellow sputum, productive cough NOS, coughing up phlegm, night 
cough present, chesty cough, bronchial cough, morning cough, evening cough, cough 
with fever, difficulty in coughing up sputum, cough symptom NOS, nocturnal cough/
wheeze, cough aggravates symptom, cough swab, cough, cough with hemorrhage. 
dNight visits; after-hours visits; follow-up visits; acute visits; home visits; hotel visits; 
nursing-home visits; residential home visits; twilight visits; visits by the practice, their 
cooperative, deputizing service, or local roster service; reactive surgery consultations; 
co-op surgery consultations; minor-injury service; medicine management; telephone 
consultation related to COPD. eNumber of consultations with code for sputum. 
C/O – sputum – symptom, sputum sample obtained, sputum examination, sputum 
sent for examination, sputum examination: abnormal; sputum: excessive – mucoid; 
sputum: mucopurulent; sputum: fetid/offensive, yellow sputum, green sputum, 
dark-green sputum, pale-green sputum, sputum appearance, brown sputum, white 
sputum, volume of sputum, copious sputum, profuse sputum, moderate sputum, 
grey sputum, sputum microscopy; sputum: pus cells present; sputum: organism 
on Gram stain, sputum microscopy NOS, sputum evidence of infection, sputum 
appears infected, sputum culture, sputum examination NOS, sputum sent for C/S, 
abnormal sputum, sputum abnormal – amount, sputum abnormal – color, sputum 
abnormal – odor, abnormal sputum – tenacious, abnormal sputum NOS, positive-
culture findings in sputum, sputum clearance, difficulty in coughing up sputum, acute 
purulent bronchitis, chesty cough, bronchial cough, productive cough NOS, coughing 
up phlegm. fHR relative to change to every 1-year difference in age.
Abbreviations: AECOPD, acute exacerbation of COPD; C/O, complaining of; C/S, 
culture and sensitivity; FEV1, forced expiratory volume in 1 second; LRTI, lower 
respiratory tract infection; MRC, Medical Research Council; NOS, not otherwise 
specified; OCS, oral corticosteroid.
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and other consultations are more likely to receive treatment 
escalation. Indeed, similar findings have been reported by 
others.18,19 Both lower age and greater use of short-acting 
bronchodilators were statistically significant predictors of 
treatment escalation in both our univariate and multivariate 
analyses. Although the HRs were relatively small, it is of note 
that they represent the impact of one unit of the covariate. 
For age, the unit is 1 year, and for short-acting bronchodila-
tor use, the unit is one extra prescription over the follow-up 
period. Age was negatively associated with treatment esca-
lation; therefore, if age increased by 1 year, the hazard is 
multiplied by 0.994. Given the poor recording of FEV
1
 in this 
patient cohort, short-acting bronchodilator use could be an 
Table 4 Multivariate analysis outcomes: predictors of treatment 
escalation
Characteristics Multivariate Cox regression 
analysis, n=10,492
HR 95% CI P-value
COPD exacerbations: compositea 2.114 1.87–2.389 ,0.0001
Asthma 1.948 1.695–2.238 ,0.0001
MRC grade (vs 1) ,0.0001
2 1.167 1.005–1.355 0.043
3 1.403 1.189–1.656 ,0.0001
4 1.757 1.42–2.174 ,0.0001
5 1.923 1.135–3.258 0.0151
Proactive COPD primary careb 1.273 1.213–1.337 ,0.0001
Reactive COPD primary carec 1.246 1.173–1.324 ,0.0001
Elective secondary care contact 1.186 1.031–1.364 0.0171
Cough symptomsd 1.101 1.055–1.149 ,0.0001
Number of SABA prescriptions 1.03 1.023–1.037 ,0.0001
Age at index datee 0.994 0.989–0.999 0.0324
FeV1 0.98 0.977–0.983 ,0.0001
Number of sputum symptomsf 0.907 0.833–0.988 0.0249
Smoking status (vs never smoked)
Current 0.544 0.424–0.7 ,0.0001
ex 0.702 0.552–0.892 0.0038
Notes: Multivariate analysis included 10,492 patients, of whom 4,591 received 
treatment escalation. Data are ordered by HR. aComposite end point: if COPD 
emergency admission or AECOPD or LRTI or OCS + antibiotic occurred on the 
same day, 1 was assigned (otherwise 0). We used time-varying covariates (so patient 
had 0 assigned until the first occurrence of any of those). This has been validated 
in a previous paper.16 bCOPD monitoring; disease monitoring by doctor; disease 
monitoring by nurse; shared-care disease monitoring; COPD 3-monthly, 6-monthly, 
and annual reviews; COPD follow-up; COPD health education; COPD-medication 
optimization; issue of COPD rescue pack or advance supply of steroid medication 
or antibiotic medication or deferred antibiotic therapy; COPD leaflet given, has 
COPD-care plan; has COPD-care pathway; has COPD clinical management plan; on 
COPD supportive care pathway; seen in COPD clinic. cNight visits; after-hours visits; 
follow-up visits; acute visits; home visits; hotel visits; nursing-home visits; residential 
home visits; twilight visits; visits by the practice, their cooperative, deputizing service, 
or local roster service; reactive surgery consultations; co-op surgery consultations; 
minor-injury service; medicine management; telephone consultation related to COPD.
dNumber of consultations with code for cough: C/O – cough, dry cough, productive 
cough-clear sputum, productive cough-green sputum productive cough-yellow sputum, 
productive cough not otherwise specified (NOS), coughing up phlegm, night cough 
present, chesty cough, bronchial cough, morning cough, evening cough, cough with 
fever, difficulty in coughing up sputum, cough symptom NOS, nocturnal cough/wheeze, 
cough aggravates symptom, cough swab, cough, cough with hemorrhage. ehr relative 
to change to every 1 year difference in age. fNumber of consultations with code for 
sputum. C/O – sputum – symptom, sputum sample obtained, sputum examination, 
sputum sent for examination, sputum examination: abnormal, sputum: excessive – 
mucoid, sputum: mucopurulent, sputum: fetid/offensive, yellow sputum, green sputum, 
dark green sputum, pale green sputum, sputum appearance, brown sputum, white 
sputum, volume of sputum, copious sputum, profuse sputum, moderate sputum, 
grey sputum, sputum microscopy, sputum: pus cells present, sputum: organism on 
gram stain, sputum microscopy NOS, sputum evidence of infection, sputum appears 
infected, sputum culture, sputum examination NOS, sputum sent for C/S, abnormal 
sputum, sputum abnormal – amount, sputum abnormal – color, sputum abnormal – 
odor, abnormal sputum – tenacious, abnormal sputum NOS, positive culture findings in 
sputum, sputum clearance, difficulty in coughing up sputum, acute purulent bronchitis, 
chesty cough, bronchial cough, productive cough NOS, coughing up phlegm.
Abbreviations: AECOPD, acute exacerbation of COPD; C/O, complaining of; C/S, 
culture and sensitivity; FEV1, forced expiratory volume in 1 second; LRTI, lower 
respiratory tract infection; MRC, Medical Research Council; NOS, not otherwise 
specified; OCS, oral corticosteroid; SABA, short-acting bronchodilator.
Table 5 Treatment escalation per GOLD 2011/2013 and 2017 
classification
Characteristic, 
n (%)
GOLD 2011/2013:1 
patients with any FEV1 
and MRC score during 
the last 12 months of 
study period
GOLD 2017:3 
patients with any 
MRC score during 
the last 12 months 
of study period
Treatment-escalation 
group, n=1,064
Treatment-
escalation group, 
n=5,090
GOLD group
a 217 (20.4) 1,393 (27.4)
B 204 (19.2) 1,900 (37.3)
C 264 (24.8) 777 (15.3)
D 379 (35.6) 1,020 (20)
Predicted FeV1
,50% 388 (36.5) –
#50% 676 (63.5) –
MrC score
1 or 2 481 (45.2) 2,170 (42.6)
$3 583 (54.8) 2,920 (57.4)
Primary-care exacerbations
#1 762 (71.6) 3,505 (68.9)
$2 302 (28.4) 1,585 (31.1)
COPD emergency admissions
0 953 (89.6) 4,758 (93.5)
$1 111 (10.4) 332 (6.5)
Patients with 
any FEV1 
measurement at 
any time during 
study period
Treatment-
escalation group, 
n=1,703
GOLD grade
1: FeV1 $80% 241 (14.2)
2: FeV1 50%–79% 907 (53.3)
3: FeV1 30%–49% 480 (28.2)
4: FeV1 ,30% 75 (4.4)
Predicted FeV1
,50% 555 (32.6)
$50% 1,148 (67.4)
Note: “–” indicates no data are available.
Abbreviations: FeV1, forced expiratory volume in 1 second; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; MRC, Medical Research Council.
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important marker to consider in the identification of patients 
who are more likely to require treatment optimization.
Our study focused on treatment escalation in patients receiv-
ing LAMA monotherapy only, and in the majority of cases we 
found that treatment escalation occurred within 2 years of treat-
ment initiation. A smaller retrospective cohort study of 3,268 
patients from the US Truven MarketScan commercial database 
likewise demonstrated dynamic changes to COPD prescriptions 
within 2 years of treatment initiation with a LABA.18 More 
specifically, within 24 months of follow-up, 16% of patients 
received treatment escalation, the majority of whom had added 
therapy (84%) progressed to triple therapy.18 This escalation 
may be a result of poor control of symptoms,18 in line with 
the present study, which suggests that treatment escalation is 
a direct result of COPD exacerbations or other symptoms that 
lead patients to contact their primary-care provider.20
A secondary objective of this study was to analyze how 
GOLD strategies guide treatment practices. Although UK 
treatment practices may be guided by NICE,13 guidelines 
from COPD-specific organizations, such as GOLD, are rou-
tinely updated to provide care paradigms reflective of recent 
clinical evidence.3 We analyzed treatment patterns according 
to GOLD grouping prior to treatment escalation by apply-
ing the GOLD 2017 strategy document, in addition to the 
GOLD 2011/2013 strategies that were contemporary to the 
study window. When data were analyzed using the 2011/2013 
GOLD strategy, 60% of the 1,064 patients who received treat-
ment escalation were classified as group C or D. When data 
were grouped according to the GOLD 2017 strategy, only 
35% of the 5,090 patients who received treatment escalation 
were classified as group C or D. Although a larger sample was 
available for the 2017 analysis, this observation indicates that 
fewer patients are recommended for ICS treatment than under 
the GOLD 2011/2013 strategy, providing that they do not have 
comorbid asthma. Our findings reflect the impact of previous 
iterations of GOLD strategies or other national guidance, such 
as NICE in the UK, but may also be a result of an increase 
over time in the proportion of patients who are receiving triple 
therapy.21 According to the GOLD 2011/2013 strategy, which 
was in place during the study window, patients in group D 
(35.6% of the population) would have been recommended 
LABA–ICS therapy.1 In fact, at the time of the study, use of 
triple therapy was common practice, and NICE 2011 guide-
lines recommended that some patients with advanced COPD 
may require maintenance with OCS when these cannot be 
withdrawn following an exacerbation,13 and many UK GPs 
would follow this practice above all other strategies. It was 
not until after the period covered in this study, with publica-
tion of such studies as WISDOM and FLAME,7,22 that many 
doctors became aware that dual bronchodilation with LABA 
and LAMA is preferable to the use of ICS-containing regimens 
as first-line therapy for the majority of patients with COPD, 
particularly if the aim of treatment is to reduce the frequency 
of exacerbations.21,23 Published in 2014, the WISDOM study 
demonstrated that exacerbating patients with severe COPD run 
in on triple therapy (according to GOLD 2011/2013) were not 
at higher risk of severe exacerbations following withdrawal 
of ICSs compared with patients who continued on triple 
therapy.7 The GOLD 2017 strategy now recommends that 
alternative treatment strategies should be considered before 
the use of ICSs, including pulmonary rehabilitation, smoking 
cessation, and the addition of LABA without ICSs. The 
present observations suggest that if the GOLD 2017 strategy 
recommendations were adopted by clinicians, there would be 
a reduction in overprescription of ICSs. Future studies may 
highlight changes in treatment practice with the uptake and 
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Figure 3 MRC breathlessness score in the treatment-escalation group.
Notes: (A) 12 Months from baseline (n=2,659) and (B) during the study and follow-up period (n=5,611). Median MRC scores at baseline were 2 and 3 during the study 
period.
Abbreviation: MRC, Medical Research Council.
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application of the GOLD 2017 strategy and other updates in 
national treatment guidance since the study was sampled.
This retrospective analysis has several strengths, but 
also some limitations. The THIN database is a very large 
data set that is representative of the UK population.24 Data 
are collected in a noninterventional way, thus reflecting 
“real-life” clinical practice. Information is continually 
updated, permitting investigation of the effects of new 
interventions/treatments. A literature search of the terms 
“THIN” and “validation” revealed that the THIN database 
has been validated for the Read codes for some but not all 
of the covariates used in this study.16,25–29 It is important 
to note that the GOLD guidelines were updated while the 
manuscript was in progress. Although GOLD guidance, 
such as GOLD 2011/2013, may have been contemporary to 
treatment practices during the study period, we additionally 
assessed patients according to GOLD 2017 grouping, in order 
to demonstrate how physicians may need to adapt their treat-
ment practices in light of new evidence. As discussed, it is 
likely that physicians were treating according to older GOLD 
strategy or other guidance contemporary to the study window, 
such as NICE 2011, and this is a possible explanation for the 
high proportion of patients in the treatment-escalation group. 
Although only a minority of the study population had FEV
1
 
measurements recorded in the database (17.7%, 2,635 of 
14,866), FEV
1
 measurements were not required for COPD 
diagnosis. Furthermore, GOLD 2017 guidelines do not use 
FEV
1
 for determining categories (and hence treatment), 
which is a welcome change in policy, as FEV
1
 has been 
reported to be a poor predictor of exacerbation risk.30
Other limitations of this study include noncompliance 
to medication prescriptions, which results in inaccurate 
assumptions of drug-related exposure; validation gaps, and 
the fact that some covariates, even though validated (eg, COPD 
exacerbations and emergency admissions), may be poorly 
reported. A Hospital Episode Statistics-linked subset of the 
THIN database could have been employed for secondary-care 
COPD exacerbations, but it would have significantly reduced 
the number of eligible patients. However, comorbidities were 
chosen using Read codes used in the Quality and Outcomes 
Framework where relevant, which are well recorded. As with 
any database study, the quality of spirometry is not always 
assured. Finally, whether the current observations on treatment 
escalation can be generalized to the wider, non-UK COPD 
population is unknown and would require further study.
Conclusion
Overall, 44% of COPD patients in UK primary care received 
treatment escalation from LAMA monotherapy to triple 
therapy (LAMA + ICS–LABA). While the presence of 
COPD exacerbations appears to be the main driver for 
treatment escalation in this cohort, according to the 2017 
GOLD strategy, 65% of the cohort who had their treatment 
escalated were classified as GOLD group A or B and would 
thus not now be recommended for treatment escalation. 
Reviewing patients’ treatment in light of updated GOLD 
strategy has the potential to reduce inappropriate prescription 
of triple therapy. If treatment escalation is needed in these 
patients, the GOLD strategy suggests the use of alternative 
strategies without ICSs.3 Given the gaps identified in EMR 
data recording, education on appropriate assessment and 
recording of data is required to guide rational treatment 
decisions and review.
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Table S1 Covariates during the analyzed baseline period
Characteristic Overall 
population, 
n=14,866
Smoking status, n (%)
Unknown 7 (0.1)
Current smoker 7,049 (47.4)
Ex-smoker 6,697 (45.1)
never smoked 1,113 (7.5)
MRC score (categorical), n (%)
Unknown 6,466 (43.5)
grade 1 1,437 (9.7)
grade 2 3,730 (25.1)
grade 3 2,134 (14.4)
grade 4 925 (6.2)
grade 5 174 (1.2)
MRC score (numeric)
Mean (SD) 2.4 (1)
FeV1, %
Mean (SD) 64 (17.9)
COPD severity, n (%)
Unknown 10,196 (68.6)
Mild 2,217 (14.9)
Moderate 1,993 (13.4)
severe 444 (3)
Very severe 16 (0.1)
Respiratory hospital referral recorded, n (%) 997 (6.7)
Elective secondary care contact (COPD secondary care 
consultation or respiratory hospital referral), n (%)
2,911 (19.6)
Acute exacerbations of COPD, mean (SD) 0.3 (1.1)
COPD emergency admissions, mean (SD) 0.04 (0.3)
LRTI events, mean (SD) 2.8 (5.2)
Cough-related events, mean (SD) 1.9 (3.3)
Sputum-related events, mean (SD) 0.5 (1.6)
Oral corticosteroid prescriptions, mean (SD) 3.7 (14.7)
Oral antibiotics prescriptions, mean (SD) 9 (11.3)
Short-acting bronchodilator prescriptions, mean (SD) 14.7 (34.2)
COPD proactive primary care consultations, mean (SD) 1.5 (2.2)
COPD reactive primary care consultations, mean (SD) 1 (2.6)
Elective secondary care consultation, n (%) 2,068 (13.9)
Composite end point: exacerbations (COPD 
emergency admission or AECOPD or LRTI or 
OCs + antibiotic), n (%)
10,805 (72.7)
Abbreviations: AECOPD, acute exacerbation of COPD; FEV1, forced expiratory 
volume in 1 second; LRTI, lower respiratory tract infection; MRC, Medical Research 
Council; OCS, oral corticosteroid.
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